3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
7
Leukemia, Myeloid, Acute
5
Neoplasms
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Fallopian Tube Neoplasms
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm, Residual
1
Mesothelioma, Malignant
1
Leukemia
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Carcinogenesis
1
Brain Neoplasms
1
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
11
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
Radiotherapy
5
dodecyl maltoside
4
apaziquone
4
tislelizumab
3
Cystoscopy
3
ALT-803
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
5-aminolevulinic acid hexyl ester
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
monalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Non-Muscle Invasive Bladder Neoplasms
×
Monatide (IMS 3015)
×
Clear all
NCT04106115
2024-12-04
DURANCE
University College, London
Phase 1/2
Recruiting
64 enrolled